Xintela AB — Investor Relations & Filings

Xintela AB is a biomedical company active in regenerative medicine and oncology. The company's technology platform is centered on the cell surface marker integrin α10β1, which is utilized to select and quality-assure therapeutic stem cells. Its primary product candidate, XSTEM®, is an allogeneic mesenchymal stem cell therapy. XSTEM® is currently in Phase I/IIa clinical development for the treatment of knee osteoarthritis and difficult-to-heal venous leg ulcers. The oncology pipeline focuses on developing targeted cancer therapies, particularly for aggressive brain tumors such as glioblastoma.